NeuroVive presents positive preclinical data in hepatocellular cancer at HCC Summit

NeuroVive Pharmaceutical’s abstract with novel preclinical cancer data related to the company’s sanglifehrin-based compounds has been accepted for presentation at the scientific conference EASL HCC Summit to take place in Geneva, Switzerland, 2-5 February, 2017.

In preclinical studies, the NeuroVive research team and its international collaborators have shown that a sub-set of these compounds exert unexpectedly potent anticancer effects. An abstract with the title Preclinical analysis of sanglifehrin-based cyclophilin inhibitors showing potential for treatment of hepatocellular carcinoma1 will be presented at the conference, the company said in its press release.

“We are now adding the exciting and challenging cancer area to our portfolio, expanding our core competence field within mitochondrial medicine. The addition of Dr. Michele Tavecchio to our team has accelerated the internal development process in this area, and the team has done a great job in exploring this new therapeutic opportunity for the company’s sanglifehrin-based compounds”, said Magnus Hansson, Chief Medical Officer at NeuroVive.

The EASL HCC Summit covers topics such as early detection, diagnosis and treatment of hepatocellular carcinoma, highlighting both the basic science and clinical science aspects of this important and rapidly evolving field.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.